Breast Cancer Research Foundation — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Breast Cancer Research Foundation appears in 92 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials92

Recruiting shown25

Roles1

SourceClinicalTrials.gov

Clinical trials

60 shown

Supporting Health Including Endocrine Treatment for Long DurationNCT07482384 · collaborator · 2026-08-04

A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS TrialNCT07443943 · collaborator · 2026-04-22

Breast Cancer Study Tracking Risk Awareness of Alcohol Consumption and Improving Knowledge in Young Adult WomenNCT07320664 · collaborator · 2026-03-19

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast CancerNCT06502691 · collaborator · 2026-02-26

Evolutionary Clinical Trial for Novel Biomarker-Driven TherapiesNCT07340541 · collaborator · 2026-02-16

Mirai-MRI: Validation of AI Models for Breast Cancer RiskNCT07121972 · collaborator · 2025-11-03

Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBCNCT07066189 · collaborator · 2025-10-17

Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.NCT06364267 · collaborator · 2025-10-01

Project SOAR (Speaking Our African American Realities) Awakenings for Black American Women Diagnosed With Breast CancerNCT07208084 · collaborator · 2025-07-25

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine TherapyNCT06953882 · collaborator · 2025-07-09

Trial of Trastuzumab Deruxtecan in Previously Treated HER2NCT06750484 · collaborator · 2025-06-20

Microbiome Immunotherapy Neoadjuvant AssessmentNCT06709651 · collaborator · 2024-10-02

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast CancerNCT06179303 · collaborator · 2024-07-22

Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast CancersNCT05846789 · collaborator · 2024-07-02

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBCNCT06245889 · collaborator · 2024-05-01

Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)NCT06322888 · collaborator · 2024-03-28

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In SituNCT06218303 · collaborator · 2024-02-07

Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer StudyNCT07214610 · collaborator · 2023-11-28

Biennial CEM in Women With a Personal History of Breast CancerNCT06105749 · collaborator · 2023-11-08

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast CancerNCT06099769 · collaborator · 2023-10-18

Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense BreastsNCT05625659 · collaborator · 2023-03-24

Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast CancerNCT04841148 · collaborator · 2021-06-01

Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCANCT03769415 · collaborator · 2018-11-06

Women Informed to Screen Depending on Measures of Risk (Wisdom Study)NCT02620852 · collaborator · 2016-08-31

Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood SamplesNCT01034033 · collaborator · 2001-08-01

Breast and Cervical Cancer Stigma in RwandaNCT07663006 · collaborator · 2026-11-01

NOT_YET_RECRUITING

Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast CancerNCT07499999 · collaborator · 2026-09-09

NOT_YET_RECRUITING

Individual Factors Associated With Care Pathways Delays in Breast Cancer in Hauts-de-France.NCT07475325 · collaborator · 2026-04-20

ACTIVE_NOT_RECRUITING

Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd TherapyNCT06680596 · collaborator · 2025-07-30

ENROLLING_BY_INVITATION

WISH, Feasibility of a Factorial DesignNCT07023822 · collaborator · 2025-06-16

Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT TrialNCT06617455 · collaborator · 2024-10-31

Psychosexual Educational Partners Program (PEPP)NCT06253182 · collaborator · 2024-04-02

ACTIVE_NOT_RECRUITING

Acupressure for Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Patients With Breast CancerNCT06228768 · collaborator · 2024-03-06

MIRAI-MRI: Comparing Screening MRI for Patients at High Risk for Breast Cancer Identified by Mirai and Tyrer-CuzickNCT05968157 · collaborator · 2024-02-04

Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or RibociclibNCT05625087 · collaborator · 2023-10-19

ACTIVE_NOT_RECRUITING

Women's Interventions for Sexual Health: WISHNCT05692960 · collaborator · 2023-02-15

Developing a Psychosexual Educational Partners Program: PEPP A Feasibility StudyNCT05070299 · collaborator · 2022-03-15

Breast Cancer BRCA1 Carriers: a Pilot StudyNCT05062174 · collaborator · 2021-11-01

Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer SurvivorsNCT04290897 · collaborator · 2021-09-29

Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based CohortsNCT04657679 · collaborator · 2021-05-20

Sleep Coach: A Mobile App to Address Insomnia Symptoms Among Cancer SurvivorsNCT04827459 · collaborator · 2021-05-12

Adaptive Nutrition and Exercise Weight Loss (A-NEW) StudyNCT04499950 · collaborator · 2021-02-08

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)NCT04443348 · collaborator · 2020-12-16

ACTIVE_NOT_RECRUITING

YES Study - Newly Diagnosed/Metastatic InterventionNCT04379414 · collaborator · 2020-09-16

ACTIVE_NOT_RECRUITING

Promoting Earlier Detection of Breast Cancer in Rwanda: Scaleup in the National Health Care SystemNCT04258085 · collaborator · 2020-07-01

Pilot Study of Effects of Duavee® on Imaging and Blood Biomarkers In Women With Menopausal SymptomsNCT04379024 · collaborator · 2020-06-01

LCCC1931:Post-treatment Intervention in Women With Breast Cancer (70y/o+)NCT04292847 · collaborator · 2020-03-12

Eurythmy Therapy (ERYT) as a Treatment Option for Fatigue in Metastatic Breast Cancer PatientsNCT04024267 · collaborator · 2020-03-10

Lifestyle Program (Scalable Nutrition and Physical Activity) for the Improvement of Nutrition and Physical Activity in Stage 0-III Breast Cancer SurvivorsNCT04200482 · collaborator · 2020-02-21

Tomosynthesis vs. Contrast-Enhanced Mammography in Women With Personal History of Breast Cancer in Western PennsylvaniaNCT04085510 · collaborator · 2019-10-23

ACTIVE_NOT_RECRUITING

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast CancerNCT03971409 · collaborator · 2019-07-08

ACTIVE_NOT_RECRUITING

Young, Empowered & Strong (YES): The Young Women's Breast Cancer Study 2- Focus on Intervention PilotNCT03913936 · collaborator · 2019-05-23

Acute Exercise Intervention in Breast Cancer SurvivorsNCT03779867 · collaborator · 2019-03-25

Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")NCT03400254 · collaborator · 2019-02-26

Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]NCT03747120 · collaborator · 2019-01-25

ACTIVE_NOT_RECRUITING

DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BCNCT03716180 · collaborator · 2018-11-05

ACTIVE_NOT_RECRUITING

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast CancerNCT03414658 · collaborator · 2018-06-21

ACTIVE_NOT_RECRUITING

Impact of Home-based Aerobic and Strength Exercises During Chemotherapy for Early Breast Cancer on Biomarkers of AgingNCT03761706 · collaborator · 2018-02-28

Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast CancerNCT03586297 · collaborator · 2017-08-27

Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCISNCT02926911 · collaborator · 2017-02-22

ACTIVE_NOT_RECRUITING

Drugs studied in this sponsor's trials

45 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Breast Cancer Research Foundation as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

paclitaxel6

capecitabine4

trastuzumab4

avelumab3

carboplatin3

cyclophosphamide3

doxorubicin3

pembrolizumab3

paclitaxel RxCUI 56946 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 6 trials capecitabine RxCUI 194000 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 4 trials trastuzumab RxCUI 224905 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 4 trials avelumab RxCUI 1875534 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 3 trials carboplatin RxCUI 40048 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 3 trials cyclophosphamide RxCUI 3002 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 3 trials doxorubicin RxCUI 3639 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 3 trials pembrolizumab RxCUI 1547545 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 3 trials tamoxifen RxCUI 10324 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 3 trials exemestane RxCUI 258494 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 2 trials metformin RxCUI 6809 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials pertuzumab RxCUI 1298944 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials placebo RxCUI 8375 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials ribociclib RxCUI 1873916 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials abemaciclib RxCUI 1946825 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial alpelisib RxCUI 2169285 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial anastrozole RxCUI 84857 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial atorvastatin RxCUI 83367 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial bazedoxifene 20 MG / estrogens, conjugated (USP) 0.45 MG Oral Tablet [Duavee] RxCUI 1441740 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial binimetinib RxCUI 2049122 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial broccoli sprout extract RxCUI 1668220 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial cisplatin RxCUI 2555 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial Contrave RxCUI 1551469 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial docetaxel RxCUI 72962 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

collaborator92

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.